Servier is already in the process of transforming ... The latter brought in acute myeloid leukaemia (AML) and cholangiocarcinoma therapy Tibsovo (ivosidenib), which was approved as a first-line ...
It was acquired by Servier alongside IDH inhibitor stablemate Tibsovo (ivosidenib), which is already approved to treat acute myeloid leukaemia. According to Servier, the results of the INDIGO ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback